HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Login (HMA-DMS)
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >Human Medicines
  • >CMDh
  • >Falsified Medicines
  • CMDh
    • About CMDh
    • Statistics
    • Agendas and Minutes
    • Press Releases
    • COVID-19
    • BREXIT
    • Nitrosamine impurities
    • Procedural Guidance
    • CMDh-Referrals
    • Product Information
    • Advice from CMDh
    • Templates
    • CMD Working Parties / Working Groups
    • Paediatric Regulation
    • Pharmacovigilance
    • Falsified Medicines
    • Questions & Answers
    • Contact Points
    • Recently Published history
  • MRI Product Index
  • Pharmacovigilance
  • Availability of Medicines
  • Publications and reports
  • National Contacts

 

  • CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive 
    (April 2018) [Track version]

 

  • Implementation plan for the introduction of the safety features on the packaging of nationally authorised medicinal products for human use (February 2016)
  • Guidance published by Member States on the implementation of the Falsified Medicines Directive (September 2018)

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/human-medicines/cmdh/falsified-medicines.html